Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 4/20 | 0.36 |
| ▸ | PYGM | P11217 | 4/20 | 0.36 |
| ▸ | CCR9 | P51686 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049497 | 0.86 | PPARG (0.41) | PPARGKDM4EGCKSMN1; SMN2 | |
| SCHEMBL4049554 | 0.84 | MCL1 (0.44) | PPARGGFERMCL1CCR2KDM4E | |
| SCHEMBL5872500 | 0.84 | GFER (0.40) | PPARGGFERMCL1CCR2KDM4E | |
| SCHEMBL5125532 | 0.84 | PPARG (0.48) | PPARGGFERMCL1CCR2KDM4E | |
| SCHEMBL5124452 | 0.84 | PPARG (0.40) | PPARGGFERMCL1CCR2KDM4E | |
| SCHEMBL5111493 | 0.83 | BRAF (0.51) | PYGLPYGMBRAF | |
| SCHEMBL14276282 | 0.83 | GFER (0.39) | PPARGGFERMCL1CCR2KDM4E | |
| SCHEMBL5117903 | 0.82 | PPARG (0.39) | PPARGGFERMCL1CCR2KDM4E | |
| SCHEMBL5125400 | 0.82 | PPARG (0.39) | PPARGGFERMCL1CCR2KDM4E | |
| SCHEMBL4047150 | 0.81 | HTR3A (0.41) | GFERMCL1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592332-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592332-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592332-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090023701-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2009-01-22 | — | — | US | disclosed |
| US-20090023701-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2009-01-22 | — | — | US | disclosed |
| US-20090023701-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2009-01-22 | — | — | US | disclosed |
| EP-1867646-A1 | Cytokine inhibitors | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070275946-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2007-11-29 | — | — | US | disclosed |
| US-20070275946-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2007-11-29 | — | — | US | disclosed |
| US-20070275946-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2007-11-29 | — | — | US | disclosed |
| US-7285545-B2 | N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285545-B2 | N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285545-B2 | N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1745036-A2 | CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005108387-A2 | CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050245536-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023701-A1 | Cytokine Inhibitors | IL1B, TNF, IL1A | PPARG 1942/4885GFER 3545/4885MCL1 1950/4885 |
| US-20050245536-A1 | Cytokine inhibitors | IL1B, TNF, IL1A | PPARG 1942/4885GFER 3545/4885MCL1 1950/4885 |
| US-20070275946-A1 | Cytokine Inhibitors | IL1B, TNF, IL1A | PPARG 1942/4885GFER 3545/4885MCL1 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.